 | • レポートコード：MRC2303G090 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の自閉症スペクトラム障害治療市場規模が、予測期間中（2022年-2027年）CAGR more than 7％で増加すると推測されています。本書では、自閉症スペクトラム障害治療の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤クラス別（抗精神病薬、選択式セロトニン再取り込み阻害薬（SSRI）/抗うつ薬、興奮剤、その他）分析、種類別（自閉スペクトラム症、アスペルガー症候群、その他）分析、流通チャネル別（病院内薬局、ドラックストア・小売薬局、オンライン薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Q BioMed Inc.、PaxMedica、Yamo Pharmaceuticals、Otsuka Pharmaceutical Co., Ltd.、F. Hoffmann-La Roche Ltd、Curemark, LLCなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の自閉症スペクトラム障害治療市場規模：薬剤クラス別 - 抗精神病薬の市場規模 - 選択式セロトニン再取り込み阻害薬（SSRI）/抗うつ薬の市場規模 - 興奮剤の市場規模 - その他自閉症スペクトラム障害治療の市場規模 ・世界の自閉症スペクトラム障害治療市場規模：種類別 - 自閉スペクトラム症治療薬の市場規模 - アスペルガー症候群治療薬の市場規模 - その他治療薬の市場規模 ・世界の自閉症スペクトラム障害治療市場規模：流通チャネル別 - 病院内薬局チャネルの市場規模 - ドラックストア・小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の自閉症スペクトラム障害治療市場規模：地域別 - 北米の自閉症スペクトラム障害治療市場規模 アメリカの自閉症スペクトラム障害治療市場規模 カナダの自閉症スペクトラム障害治療市場規模 メキシコの自閉症スペクトラム障害治療市場規模 … - ヨーロッパの自閉症スペクトラム障害治療市場規模 ドイツの自閉症スペクトラム障害治療市場規模 イギリスの自閉症スペクトラム障害治療市場規模 フランスの自閉症スペクトラム障害治療市場規模 … - アジア太平洋の自閉症スペクトラム障害治療市場規模 中国の自閉症スペクトラム障害治療市場規模 日本の自閉症スペクトラム障害治療市場規模 インドの自閉症スペクトラム障害治療市場規模 … - 南米/中東の自閉症スペクトラム障害治療市場規模 ブラジルの自閉症スペクトラム障害治療市場規模 アルゼンチンの自閉症スペクトラム障害治療市場規模 サウジアラビアの自閉症スペクトラム障害治療市場規模 ・競争状況 ・市場機会・将来動向 |
The autism spectrum disorders treatment market is expected to register a CAGR of more than 7% over the forecast period, 2022-2027.
The COVID-19 pandemic has significantly impacted the autism disorders treatment market. This can be attributed to the fact that the pandemic caused supply chain disruptions in the pharmaceutical industry which led to problems in seeking treatment for autism spectrum disorders. Thus, the pandemic had a short-term negative impact on the market. In addition, as per a June 2021 published article titled, “Leveraging Technology for the Wellbeing of Individuals With Autism Spectrum Disorder and Their Families During Covid-19”, one-way technology can be used during the pandemic for families with autism spectrum disorder (ASD) is through telehealth, which refers to providing various remote services electronically, such as patient care, education, and monitoring. Thus, telehealth has aided in meeting the rising demand for autism spectrum disorder treatment, thereby contributing to the market growth. Also, as per a December 2021 published study titled, “Coping with autism during lockdown period of the COVID-19 pandemic”, the COVID-19 pandemic disrupted routines, triggered behavioral issues in individuals with ASD, and impacted the coping skills of both individuals and families, along with the mental health and well-being of the family. Such studies indicate the significantly high demand for autism spectrum disorders treatment amid the pandemic, thereby depicting an overall positive impact on the market.
The growth of the market can be attributed to the factors such as the increasing burden of autism spectrum disorder worldwide, rising awareness about the condition and available treatment options for autism spectrum disorder, as well as the growing number of investments in autism spectrum disorder.
For instance, as per a March 2022 update by the World Health Organization (WHO), about one in 100 children has autism. In addition, as per an October 2021 published study titled “Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review,” thirteen studies on the prevalence of autism spectrum disorder and 33 on the prevalence of co-morbidities were included. Prevalence of ASD was 1.70 and 1.85% in the United States in children aged 4 and 8 years, respectively, while the prevalence in Europe ranged between 0.38 and 1.55%. Additionally, current evidence is supportive of a global increase in autism spectrum disorder prevalence over the past years. However, the growing number of investments is also a major factor driving the market growth. For instance, in November 2021, Yamo Pharmaceuticals, LLC, reported that The Autism Impact Fund had made a capital investment in Yamo to support a Phase II study of L1-79 in adolescents and adults with an autism spectrum disorder. L1-79, the company’s lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in autism spectrum disorder (ASD) and thus impact the socialization and communication symptoms in individuals with ASD.
However, the high cost of autism spectrum disorder treatment and diagnosis, as well as stringent regulations about product approval, are the major factors hindering the market growth.
Autism Spectrum Disorders Treatment Market Trends
Autistic Disorder Segment is Expected to Hold a Major Market Share in the Autism Spectrum Disorders Treatment Market
By type, the autistic disorders segment is expected to hold a significant market share attributing to the factors such as increasing research and development as well as the initiatives undertaken by the market players and government. People with autistic disorder usually have significant language delays, social and communication challenges, and unusual behaviors and interests, and people with autistic disorder also have an intellectual disability.
In November 2021, a group of Indian researchers developed a compound called “6BIO” that can provide a better method to treat Autism Spectrum Disorder (ASD). They have determined the potency of the compound in a pre-clinical mice model. This is the first compound that has been proved in pre-clinical evaluation to have the potential for improving daily activities like learning and recollecting new tasks in patients with ASD/ Intellectual disability (ID).
In addition, in October 2021, Axial Therapeutics obtained funding for a Phase II autism trial with USD 37 million Series C to further work on neurological diseases.
Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
Within North America, the United States has held a significant share of the market. The major factors contributing to the market growth are the burden of autism spectrum disorders, increasing research and development as well as growing number of investments.
For instance, as per a March 2022 update by the Centers for Disease Control and Prevention (CDC), about 1 in 44 children has been identified with autism spectrum disorder (ASD). Thus, there is a growing need for autism spectrum disorder treatment in the country.
The increasing number of initiatives undertaken by the market players is contributing to the market growth. For instance, in April 2022, XRHealth, the gateway to the healthcare metaverse, reported that their virtual/augmented reality therapy is available in the United States to treat patients with autism. Such developments are expected to fuel the development of drugs, thereby proliferating market growth.
In addition, in June 2021, Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, reported that the United States Food and Drug Administration (FDA) had granted the company’s De Novo classification request for its autism diagnosis aid.
Thus, due to the above-mentioned factors, the market is expected to witness significant growth over the forecast period.
Autism Spectrum Disorders Treatment Market Competitor Analysis
The autism spectrum disorders treatment market is competitive and nearly consolidated with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, and Q BioMed Inc., among other players.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Autism Spectrum Disorder (ASD) Worldwide
4.2.2 Rising Awareness Pertaining ASD and Growing Number of Investments
4.3 Market Restraints
4.3.1 High Cost of Autism Spectrum Disorder Treatment and Diagnosis
4.3.2 Stringent Regulations Pertaining to Product Approval
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Drug Class
5.1.1 Antipsychotic Drugs
5.1.2 SSRIs/Antidepressants
5.1.3 Stimulants
5.1.4 Other Drug Classes
5.2 By Type
5.2.1 Autistic Disorder
5.2.2 Asperger’s Sydrome
5.2.3 Other Types
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Drug Stores and Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle- East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Q BioMed Inc.
6.1.2 PaxMedica
6.1.3 Yamo Pharmaceuticals
6.1.4 Otsuka Pharmaceutical Co., Ltd.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Curemark, LLC
6.1.7 Zynerba Pharmaceuticals, Inc
6.1.8 Axial Therapeutics
6.1.9 Novartis AG
6.1.10 STALICLA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS